Skip to main content
main-content

06-06-2021 | ASCO 2021 | Conference coverage | Video

VISION trial supports LuPSMA-targeting therapy for mCRPC

Michael Morris discusses the VISION trial findings demonstrating a survival benefit with LuPSMA-targeted therapy for men with heavily pretreated metastatic castration-resistant prostate cancer (7:44).

Read transcript

2021 ASCO Annual Meeting coverage

Access news and expert commentary from the 2021 ASCO Annual Meeting

Image Credits